PCRX:NSD-Pacira Pharmaceuticals Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 57.95

Change

+0.22 (+0.38)%

Market Cap

USD 2.65B

Volume

0.36M

Avg Analyst Target

USD 81.20 (+40.12%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

PCRX Stock Forecast & Price:
Based on the Pacira Pharmaceuticals Inc stock forecasts from 5 analysts, the average analyst target price for Pacira Pharmaceuticals Inc is USD 81.20 over the next 12 months. Pacira Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Pacira Pharmaceuticals Inc is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Pacira Pharmaceuticals Inc’s stock price was USD 57.95. Pacira Pharmaceuticals Inc’s stock price has changed by -0.63% over the past week, +5.36% over the past month and +0.71% over the last year.

About Pacira Pharmaceuticals Inc (PCRX:NSD)

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide exten ...Read More

Company Website : https://www.pacira.com

Address : 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609

Employees : 697

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.84

52 Week High : 82.16

Short Ratio : 9.55

52 Week Low : 45.05

Shorted Shares : 4,583,273

200 Day Moving Average : 62.48

Shorted Shares Previous Month : 4,592,197

50 Day Moving Average : 56.46

Shares Held By Insiders : 1.15%

Short Percentage : 13.71%

Shares Held by Institutions : 110.23%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX Neurocrine Biosciences Inc

-1.28 (-1.19%)

 USD10.27B 826.08 212.29
MYL Mylan N.V

N/A

 USD8.59B 30.73 11.86
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

-0.32 (-0.38%)

 USD5.75B 199.29 50.44
ITCI Intracellular Th

+1.28 (+2.44%)

 USD4.96B N/A -15.27
HCM HUTCHMED DRC

-0.24 (-1.73%)

 USD2.40B 17.69 -5.96
TLRY Tilray Inc

-0.09 (-2.10%)

 USD2.34B 9.83 -10.33
ALVO Alvotech Ordinary Shares

+0.11 (+1.20%)

 USD2.27B N/A -134.36
DVAX Dynavax Technologies Corporati..

-1.38 (-8.83%)

 USD1.98B 9.89 7.28

ETFs Containing PCRX

Symbol Name Weight Mer Price(Change) Market Cap
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.58 %

-0.21 (-0.27%)

 USD0.34B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.69% 76% C 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.69% 76% C 64% D
Trailing 12 Months  
Capital Gain 0.47% 83% B 74% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.47% 83% B 72% C-
Trailing 5 Years  
Capital Gain 60.75% 82% B- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.75% 82% B- 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 16.43% 76% C 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.43% 76% C 75% C
Risk Return Profile  
Volatility (Standard Deviation) 28.55% 87% B+ 58% F
Risk Adjusted Return 57.55% 96% A 87% B+
Market Capitalization 2.65B 96% A 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 68.73 15% F 14% F
Price/Book Ratio 3.49 32% F 28% F
Price / Cash Flow Ratio 21.04 11% F 16% F
EV/EBITDA 22.46 7% F 13% F
Management Effectiveness  
Return on Equity 5.44% 83% B 57% F
Return on Invested Capital 5.28% 78% C+ 63% D
Return on Assets 4.55% 84% B 79% C+
Debt to Equity Ratio 92.35% 33% F 23% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 9.55 15% F 14% F
Short Percent 13.71% 20% F 13% F
Beta 0.84 65% D 66% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.